Results

AbbVie Inc.

06/12/2021 | Press release | Distributed by Public on 06/12/2021 05:13

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line[...]